Noa Bregman

Key facts

• Principal investigator of the Tel Aviv natural history study of preclinical genetic CJD (NCT05746715) and first author of its protocol.
• Single site in Israel (Cognitive Neurology Unit, Tel Aviv Medical Center), recruiting; PI Noa Bregman; two groups: genetic CJD patients and first-degree healthy relatives (carriers and non-carriers of E200K); yearly in-depth visits for four years with clinical evaluation, blood and urine, gait, brain MRI, lumbar puncture and polysomnography; requires willingness to undergo genetic testing.
• Corresponding author of the BMC Neurology protocol (April 2023) for the cross-sectional and longitudinal study of patients and first-degree relatives.
• Co-author of the March 2025 JNNP paper on white matter abnormalities in healthy E200K carriers with raised CSF tau, funded by Ionis.
• The protocol aims to identify biomarkers of preclinical CJD and risk factors for phenoconversion in the largest known at-risk population.
• The registry lists individual participant data sharing as no.

Timeline

1. 2023Registry listing updated.
2. 2023Protocol published.
3. 2025JNNP paper published.